Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Adhd

    Pennsylvania

    Search
    Adhd
    Pennsylvania
    Show Map
    Map View
    Pennsylvania
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      76 Adhd Trials near Pennsylvania

      Power is an online platform that helps thousands of Adhd patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Centanafadine for ADHD

      Media, Pennsylvania
      This trial aims to test the safety and tolerability of a daily ADHD medication in children and teens aged 4-17. The medication releases its effects slowly over the day to help manage symptoms consistently. HLD200 is a form of methylphenidate designed to provide benefits from morning until evening.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:4 - 18

      Key Eligibility Criteria

      Disqualifiers:Tourette's, Severe Anxiety, Psychosis, Autism, MDD, Others

      680 Participants Needed

      SPN-812 for ADHD

      Hershey, Pennsylvania
      This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:48 - 69

      Key Eligibility Criteria

      Disqualifiers:Major Psychiatric, Neurological Disorders, Others
      Must Not Be Taking:CYP1A2 Substrates

      286 Participants Needed

      Behavioral Parenting Intervention for ADHD

      Hershey, Pennsylvania
      This trial examines if a parent training program can help children aged 5-12 with ADHD and mild oppositional behaviors. The program teaches parents to manage their children's actions through positive reinforcement and clear consequences. The study will see if parents' ability to control their own emotions affects the program's success.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:5 - 12

      Key Eligibility Criteria

      Disqualifiers:Non English Speaking, Intellectual Delay, Autistic Traits, Others

      65 Participants Needed

      MomMA Intervention for ADHD

      Pittsburgh, Pennsylvania
      The goal of this study is to test a behavioral program for pregnant individuals with ADHD. This behavioral program focuses on skills for managing ADHD and related symptoms in pregnancy and postpartum. This pilot effectiveness-implementation trial aims to (1) preliminarily evaluate the MomMA behavioral intervention compared to treatment as usual (TAU) on clinical outcomes and (2) evaluate implementation outcomes, including feasibility and acceptability of clinic screening within existing OB workflows; assessment and intervention protocols; provider training/fidelity to manual; and all other study protocols from the perspective of real-world providers and participants.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Substance Use, Intellectual Disability, Bipolar, Others

      120 Participants Needed

      Caregiver Strategies for ADHD

      Philadelphia, Pennsylvania
      The purpose of this study is to field pre-test an implementation strategy resource package that aims to support caregivers in using behavioral interventions for children with hyperactive, inattentive, or impulsive behaviors. Enrolled caregivers will be assigned to use the resource package with their children. The research team will collect quantitative and qualitative data regarding acceptability, appropriateness, and feasibility, in preparation for a randomized pilot study.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Unphased
      Age:4+

      Key Eligibility Criteria

      Disqualifiers:Acute Harm Risk, Intellectual Disability, Others

      33 Participants Needed

      Transcranial Focused Ultrasound for Impulsivity

      Pittsburgh, Pennsylvania
      The investigators aim to examine the immediate effect of transcranial focused ultrasound (tFUS) on brain activity in healthy adults.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 45

      Key Eligibility Criteria

      Disqualifiers:MDD, Psychosis, Bipolar, Epilepsy, Others
      Must Not Be Taking:Psychotropics, Stimulants

      31 Participants Needed

      Behavior Therapy for ADHD in Primary Care

      Philadelphia, Pennsylvania
      This trial tests a special behavior therapy provided in the doctor's office for low-income children with ADHD. The therapy works closely with the child's regular doctor to help improve behavior, school performance, and relationships.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:5 - 11

      Key Eligibility Criteria

      Disqualifiers:Autism, Intellectual Disability, Others

      300 Participants Needed

      MomMA Intervention for ADHD

      Pittsburgh, Pennsylvania
      The study will develop and test a behavioral program for pregnant individuals with Attention-Deficit/Hyperactivity Disorder (ADHD). This behavioral program will include skills for managing ADHD and related symptoms during pregnancy and after delivery and will be taught by a behavioral therapist in OB care settings.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 55
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Substance Use Disorder, Intellectual Disability, Severe Mental Illness, High Risk Pregnancies, Others

      10 Participants Needed

      Gameplay Therapy for Attention Deficit Hyperactivity Disorder (ADHD)

      Berlin, New Jersey
      This trial is testing a video game that adults with ADHD can play at home to help manage their symptoms. The game aims to improve attention and reduce hyperactivity by training the brain. Researchers are studying if this new approach is safe and effective. The Secret Trail of Moon (TSTM) is a virtual reality game designed for cognitive training related to core ADHD symptoms and executive dysfunction.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:22 - 55

      Key Eligibility Criteria

      Disqualifiers:PTSD, Schizophrenia, Bipolar, Autism, Others
      Must Be Taking:ADHD Medication

      194 Participants Needed

      Behavior Parent Education for ADHD in Pre-Kindergarteners

      Bethlehem, Pennsylvania
      This trial tests a parent training program called PEAK for parents of young children with ADHD. The program teaches practical strategies to manage behavior and improve early academic skills through interactive sessions available both face-to-face and online.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Age:3 - 5

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      180 Participants Needed

      CNS Stimulants for ADHD

      Hershey, Pennsylvania
      Impulsive Aggression and chronic irritability (IACI) often occur together and are one of the most common reasons children present for behavioral health (BH) care. ADHD frequently associated with IACI as upwards of 50% of youth with ADHD manifest impairing IACI levels. IACI is the most common reason that children with ADHD are prescribed antipsychotics and admitted to inpatient BH units. Systematic dose optimization of CNS stimulants improves levels of IACI, reducing the need for these more intensive and burdensome treatments. However, response varies, with over half of children with ADHD showing meaningful improvement, upwards of 40% receiving minimal benefit and 3 to 10% exhibiting increased IACI levels. Symptom levels of ADHD or IACI and other demographic variables are of limited utility for predicting response, suggesting the need to move beyond symptoms in the search for treatment predictors. Youth with ADHD and IACI struggle with multiple aspects reinforcement learning (RL), defined as learning from interactions with the environment to reach a goal. Successful RL efforts tap multiple cognitive functions. In controlled laboratory tasks, youth with IACI and various BH disorders exhibit excessive behavioral and neural response to receiving reward (reward responsiveness), difficulty processing environmental cues to adapt behavior to meet a goal (set shifting/goal updating) and impaired ability to flexibly attend to relevant stimuli when blocked from a goal (frustrative nonreward). Event related potentials (ERP) are small electrical responses in the brain in response to specific events or stimuli measured by electroencephalogram (EEG) testing. ERPs exist that can serve as established neural measures of each of these cognitive functions offering a child friendly means to assess their contribution to observable levels of IACI. CNS stimulants improve functioning in these specific realms and impact associated ERPs to the degree that differences between ADHD and non-ADHD youth disappear. This study will examine the capacity of these ERPs to predict levels of IACI exhibited by children with ADHD when at home. Investigators will then assess if variability across children in the capacity of CNS stimulants to impact RL associated ERPs accounts for differences in the clinical effects of CNS stimulant medications to improve IACI at home using a multimethod battery integrating ERPs, parent report and task performance. Specifically, investigators will examine variance in the reward positivity (RewP) ERP when receiving reward feedback, the switch positivity (SwP) ERP measuring mental effort when cued to shift set and the change in P3b amplitude measuring attention allocation when transitioning from reward to nonreward on a go-no-go task. To achieve these aims, 136 children with ADHD and elevated IACI levels will have their CNS stimulant dose optimized over six weeks and then complete a two week within subjects crossover trial of placebo versus optimal dose. ERP collection will be completed within each blinded week. Parent ratings will be gathered 3 times per day including during peak and off-peak times of medication efficacy to capture the variance in IACI levels within the day and disentangle reports of worsening IACI related to loss of previously beneficial medication effects versus those most likely related to a direct adverse response to medication.
      Stay on current meds

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 4
      Age:7 - 12

      Key Eligibility Criteria

      Disqualifiers:Autism, Bipolar, Intellectual Delay, Others
      Must Be Taking:CNS Stimulants

      136 Participants Needed

      Sensory Intervention for Sleep Issues in ADHD

      Pittsburgh, Pennsylvania
      The goal of this study is test the hypothesis that sleep problems for children with ADHD are linked to sensory over-responsivity, a type of sensory processing difference that causes a person to interpret daily sensory input as stressful. This study examines the impact of sensory over-responsivity on bedtime arousal levels in 30 children with ADHD (ages 6-13). We will also test a bedtime intervention targeting sensory over-responsivity at bedtime and examine how it impacts bedtime arousal levels and sleep difficulties.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:6 - 13

      Key Eligibility Criteria

      Disqualifiers:Sleep Apnea, Narcolepsy, Depression, Others

      30 Participants Needed

      Quillivant XR for ADHD in Down Syndrome

      Pittsburgh, Pennsylvania
      Children with Down syndrome (DS) have a 3-5 time greater prevalence of Attention Deficit Hyperactivity Disorder (ADHD) than typically developing (TD) children. Despite this higher risk of ADHD, rates of stimulant medication treatment are disproportionately low in children with DS+ADHD, even though stimulants are the most efficacious ADHD treatment and are recommended by consensus guidelines for use in children with intellectual disability and ADHD. The investigators propose the first randomized clinical trial (RCT) of stimulant medication in children with DS+ADHD. This RCT may provide evidence regarding the short- and long-term safety and efficacy of stimulant use in children with DS+ADHD, both with and without CHD. All children enrolled in the study will complete a comprehensive assessment battery evaluating ADHD diagnostic criteria, as well as behavioral, cognitive, academic, and functional impairments.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:6 - 17

      Key Eligibility Criteria

      Disqualifiers:Psychoses, Bipolar, Organic Brain Injury, Heart Conditions, Severe OSA, Pregnancy, Others
      Must Not Be Taking:ADHD Stimulants, MAOIs

      100 Participants Needed

      Digital Therapy Apps for Childhood Behavior Problems

      Pittsburgh, Pennsylvania
      This trial tests a smartphone app called UseIt! to help parents manage their children's disruptive behaviors. The app can be used alone or with help from a coach. It teaches parents effective behavior management techniques.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:5 - 8

      Key Eligibility Criteria

      Disqualifiers:Bipolar, Major Depression, Pervasive Developmental, Others

      324 Participants Needed

      HOPS Intervention for ADHD

      Philadelphia, Pennsylvania
      The purpose of this current study is to conduct a conceptual replication with an independent evaluation team of the randomized controlled trial conducted by Langberg and colleagues, which demonstrated the efficacy of the Homework, Organization, and Planning Skills (HOPS) intervention. The study will be conducted under routine practice conditions with school staff serving as interventionists; the study sample will include the broad range of students with organization, time management, and planning problems. The study will examine how implementation factors (fidelity, engagement, working alliance) are related to outcomes, and it will explore the potential moderating role of school organization factors on outcomes.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:11 - 15

      Key Eligibility Criteria

      Disqualifiers:Special Education, Non-English Speakers, Others

      240 Participants Needed

      Stimulant Medications for ADHD in Autism Spectrum Disorder

      Pittsburgh, Pennsylvania
      This study is a pragmatic clinical trial examining the comparative effectiveness of two stimulant medications (methylphenidate and amphetamine) in the treatment of ADHD in children and adolescents with autism. Using a sequential, multiple assignment randomization trial (SMART) design the study will not only assess these two medications but also the role of an increasingly popular class of ADHD medication, the alpha-2 agonists. Findings from this study will help improve clinicians' approach to medication selection and reduce the repeated trials of multiple medications that are current standard care.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:4 - 17

      Key Eligibility Criteria

      Disqualifiers:Unstable Medications, Others
      Must Not Be Taking:ADHD Medications

      500 Participants Needed

      Implementation Support Strategies for Disruptive Behaviors

      Pittsburgh, Pennsylvania
      In a prior application (MH064372), the investigators' treatment research program (Services for Kids In Primary-care, SKIP) developed and tested a chronic care model-based intervention, called Doctor Office Collaborative Care (DOCC), that was found to be effective in the management of childhood behavior problems and comorbid ADHD. In the "SKIP for PA Study", the investigators propose to conduct a randomized clinical trial to evaluate the effects of team- and practice leadership-level implementation strategies designed to enhance the use and uptake of DOCC in diverse pediatric primary care offices.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Already Enrolled Caregiver

      450 Participants Needed

      Sleep-Focused Parenting Intervention for Preschoolers with ADHD

      Pittsburgh, Pennsylvania
      The goal of this pilot clinical effectiveness trial is to compare a brief parent behavioral intervention (PBI) to a modified sleep focused PBI (SF-PBI) delivered by therapists in pediatric primary care for families of children 3-5 years old with sleep problems and early ADHD symptoms. The main aims are to: Aim 1: Demonstrate the acceptability, feasibility, and appropriateness of the sleep focused PBI (SF-PBI) delivered in pediatric primary care for preschool-aged children (3-5 years old) at elevated risk for ADHD. Aim 2: Examine change in target engagement (sleep) and ADHD symptoms among preschool-aged children at elevated risk for ADHD receiving SF-PBI compared to standard PBI.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:3 - 5

      Key Eligibility Criteria

      Disqualifiers:Narcolepsy, Obstructive Sleep Apnea, Others

      50 Participants Needed

      Measurement Feedback App for Autism Spectrum Disorder

      Philadelphia, Pennsylvania
      The goal of this clinical trial is to test whether a smartphone-based data collection and feedback application ("Footsteps") improves the quality of behavioral data collected by one-to-one aides and leads to better youth mental health outcomes in school-aged youth (ages 4-17) who receive one-to-one support in schools. The main questions it aims to answer are: 1. Does the Footsteps app improve aides' data collection quality (i.e., consistency, timeliness, and completeness)? 2. Does Footsteps use lead to improved youth behavioral health outcomes (e.g., SDQ, YTP, GAS scores)? 3. Does Footsteps improve communication and supervision processes between aides and clinical supervisors? Researchers will compare aides using Footsteps to those using a "data collection only" control app to see if Footsteps leads to higher quality data collection, enhanced supervisory communication, and better youth outcomes. Participants will: * Use either Footsteps or a control app to record de-identified data on one client's behaviors and skills over 12 weeks * Complete biweekly online surveys about data collection experiences, youth progress, and aide-supervisor communication * Participate in a virtual intake and post-trial meeting * (For a subset) Participate in a 30-45 minute qualitative interview about their experience using the app
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Pilot Trial Participants

      200 Participants Needed

      Oxymetazoline Drops for Drooping Eyelid

      Hershey, Pennsylvania
      After an episode of facial paralysis, as nerves recover, they aberrantly regenerate and send additional branches to the incorrect muscles in addition to the intended muscle. This leads to what is known as Aberrant Regeneration Syndrome, Post-paralysis Synkinesis, or Nonflaccid Facial Paralysis. It is characterized by poor facial symmetry and function, hypertonic facial muscles at rest, and abnormal facial movements. One sequela is acquired blepharoptosis causing a smaller ocular aperture, visual field obstruction, cosmetic deformity, and abnormal periocular spasms. This study aims to evaluate an FDA approved medication for acquired blepharoptosis due to synkinesis/hyperkinesis as an adjunct to treatment.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Under 18, Glaucoma, Lagophthalmos, Others
      Must Not Be Taking:Cardiac Glycosides, MAO Inhibitors

      48 Participants Needed

      Why Other Patients Applied

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58
      Match to a Adhd Trial

      Videolaryngoscope vs Regular Laryngoscope for Infant Intubation

      Philadelphia, Pennsylvania
      Nasotracheal Intubation with Videolaryngoscopy versus Direct Laryngoscopy in Infants (NasoVISI) Trial is a prospective randomized multicenter study. The study will be conducted at 8 centers in the United States. It is expected that approximately 700 subjects enrolled to product 670 evaluable subjects.The randomization is 1:1 naso tracheal intubation with the Storz C-Mac Video Videolaryngoscopy (VL) or the Standard Direct Laryngoscope (DL). The primary objective is to compare the nasotracheal intubation (NTI) first attempt success rate using VL vs. DL in infants 0-365 days of age presenting for cardiothoracic surgery and cardiac catheterizations.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Age:1+

      Key Eligibility Criteria

      Disqualifiers:Less Than 36 Weeks, Less Than 2 Kg, History Of Difficult Intubation, Others
      Must Be Taking:Neuromuscular Blockers

      1400 Participants Needed

      Methadone for Addiction

      Philadelphia, Pennsylvania
      The goal of this study is to develop a loading dose approach to starting methadone to treat opioid use disorder with fentanyl use ("fentanyl OUD", herein). This study is a participant- and assessor- blinded dose-finding study using the Bayesian optimal interval (BOIN) design. Investigators aim to recruit n=24 participants with fentanyl OUD to a research unit for monitored methadone initiation. Participants will be randomized to standard initiation vs. loading dose initiation at one of four doses.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Cardiac Issues, Hepatic Dysfunction, Others
      Must Not Be Taking:Buprenorphine, Benzodiazepines, Alcohol, Others

      24 Participants Needed

      Implementation Strategy for HIV Prevention in Drug Addiction

      Pittsburgh, Pennsylvania
      In the U.S., an estimated 3.6 million people who inject drugs (PWID) face a growing yet preventable health crisis, with rising cases of serious injection-related infections (SIRI), including HIV, due to limited access to two high-priority interventions: sterile injection equipment and daily oral HIV pre-exposure prophylaxis (PrEP). Outpatient clinics represent an opportune venue to implement these interventions. Yet most clinical providers in these settings do not currently provide them, contributing to a wide gap between evidence and routine practice. The Prescribe to Prevent HIV (P2PH) trial is a participatory study designed to co-develop and pilot test a set of implementation strategies to support outpatients clinics in offering sterile injection equipment and PrEP with the goal of reducing the risk of HIV and SIRI among PWID.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Under 18, Non-English, Legal Issues, Others

      536 Participants Needed

      Collaborative Care for Substance Use Disorders

      Lancaster, Pennsylvania
      The purpose of this trial is to test the efficacy of a collaborative care intervention to address opioid- and/or stimulant-involved polysubstance use in adult primary care patients with moderate to severe substance use disorders (SUD). The primary aims are to reduce days of opioid use (illicit or nonmedical opioid use), days of illicit stimulant use (cocaine, methamphetamine), and days of heavy alcohol use.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Jail, Recent SUD Treatment, Others
      Must Not Be Taking:MOUD

      350 Participants Needed

      INDV-6001 for Opioid Use Disorder

      Marlton, New Jersey
      This is a multicentre, open-label, multiple dose study of INDV-6001 in adult participants with moderate or severe OUD as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5). The current study will evaluate the pharmacokinetics (PK), safety, and tolerability of INDV-6001 following multiple doses in participants with OUD to select optimum dosing regimens for future studies. Prior to receiving INDV-6001, participants will be stabilised on 12-16 mg of transmucosal (TM) BUP (SUBOXONE®) or will transition from a 100-mg monthly maintenance dose of SC extended-release BUP (SUBLOCADE®). This study will also evaluate the use of alternative injection sites (thigh, back of upper arm), which may be desirable in this patient population for the anticipated extended durations of treatment.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Chronic Opioid Treatment, QT Prolongation, Others
      Must Be Taking:Buprenorphine

      123 Participants Needed

      Semaglutide for Opioid Addiction

      Harrisburg, Pennsylvania
      The goal of this clinical trial is to learn if semaglutide can reduce illicit opioid use in adults in outpatient treatment for opioid use disorder, and who are receiving either buprenorphine or methadone maintenance treatment. The main question it aims to answer is: • Does semaglutide increase the likelihood that participants will refrain from using illicit and nonprescribed opioids? The investigators will compare semaglutide to a placebo (a needle prick that contains no drug) to see if semaglutide works to reduce use of illicit and nonprescribed opioids. The participants will: * Take semaglutide or a placebo every week for 12 weeks * Visit the clinic every week for urine drug screening and pregnancy testing, vital signs, and to complete mental health and drug use questionnaires * Complete smartphone surveys sent at set times during the study

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Cardiovascular Disease, Psychiatric Disorders, Others
      Must Be Taking:Buprenorphine, Methadone

      200 Participants Needed

      Opioid Tapering for Opiate Dependence

      Philadephia, Pennsylvania
      This is a pilot study in which patients taking opioids chronically who are scheduled for spine surgery at least 4 weeks in advance will be randomly assigned to one of two groups: opioid tapering with education alone or opioid tapering with education plus cognitive behavioral therapy (CBT). The primary objective is to determine the proportion of each group that is successful in achieving their opioid tapering goals by the time of surgery.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Non-English-speaking, Positive Drug Screen, Others
      Must Be Taking:Opioids

      45 Participants Needed

      Nicotine Pouches for Tobacco Addiction

      Hershey, Pennsylvania
      The purpose of this clinical trial is to understand the health effects of a new oral nicotine pouch, and also to understand if this product can help reduce traditional cigarette smoking. The main aims are: 1. Understand the impact of nicotine pouch use on toxicant exposure biomarkers, and indicators of potential harms to health. 2. Examine the influence of nicotine pouch use on conventional tobacco product use (cigarettes). Participants will be randomized to one of six nicotine pouch groups (3 nicotine strengths, each with 2 potential flavors) to use over 16 weeks and asked to reduce their cigarette smoking over that time by at least 75% by substituting with the use of the nicotine pouches. Researchers will compare the outcomes of the different nicotine pouch strengths and flavors to each other. Participants will be asked to complete study questionnaires and provide urine, exhaled carbon monoxide, and mouth cell samples, and other health measurements.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:21 - 70

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Respiratory Diseases, Kidney Disease, Others

      375 Participants Needed

      TEST Intervention for Liver Transplant Adherence

      Philadelphia, Pennsylvania
      Liver transplantation is increasingly performed for older adults with multiple comorbidities. Medication adherence is key to maintaining proper function of the transplanted liver and optimize health; however, adhering to post-transplant treatment is complex. This trial will study how available technology combined with transplant center resources and caregiver support can optimize medication adherence, quality of life, and health outcomes among new liver transplant recipients at 3 centers.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Severe Vision, Hearing, Cognitive Impairments

      360 Participants Needed

      Chatbot Monitoring for Lung Cancer Medication Adherence

      Philadelphia, Pennsylvania
      The objective of this project is to identify effective strategies to help patients with lung cancer manage side effects and achieve optimal adherence to oral targeted therapies. To achieve this objective, we will evaluate the effect of a novel, bidirectional conversational agent, compared to usual care, on adherence to oral targeted therapies using a two-arm randomized controlled trial, and explore how multilevel factors impact the acceptability and effectiveness of this strategy by collecting qualitative and quantitative data from clinicians and patients.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Concurrent Trial, Others
      Must Be Taking:Oral Targeted Therapies

      75 Participants Needed

      123

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Popular Searches

      By Condition

      Depression Clinical Trials

      Anxiety Clinical Trials

      Schizophrenia Clinical Trials

      ADHD Clinical Trials

      Bipolar Disorder Clinical Trials

      Multiple Sclerosis Clinical Trials

      Autism Clinical Trials

      Treatment Resistant Depression Clinical Trials

      Borderline Personality Disorder Clinical Trials

      Social Anxiety Disorder Clinical Trials

      Parkinson's Disease Clinical Trials

      Alzheimer's Disease Clinical Trials

      By Location

      Clinical Trials in California

      Clinical Trials in Florida

      Clinical Trials in Texas

      Clinical Trials in New York

      Clinical Trials in Ohio

      Clinical Trials in Illinois

      Clinical Trials in Pennsylvania

      Clinical Trials in Michigan

      Clinical Trials in North Carolina

      Clinical Trials in Massachusetts

      Clinical Trials in Missouri

      Clinical Trials in Minnesota

      Other People Viewed

      By Subject

      Top Lung Cancer Clinical Trials near Miami, FL

      Top Insomnia Clinical Trials

      Top Clinical Trials near Anderson, SC

      Top Colorectal Cancer Clinical Trials near Albuquerque, NM

      Top Clinical Trials near Hanover, NH

      Top Breast Cancer Clinical Trials near Baltimore, MD

      Top Dyspepsia Clinical Trials

      Top Clinical Trials near Fairview Heights, IL

      Top Clinical Trials near Greensboro, NC

      18 Eczema Trials near Alexandria, VA

      Top Pain Clinical Trials

      Top Clinical Trials near Desoto, TX

      By Trial

      Omega 3 Fatty Acids for Breast Cancer Prevention

      Home Care After Stem Cell Transplantation

      Meaning-Centered Psychotherapy for Cancer Caregiver Support

      Psilocybin-Enhanced Psychotherapy for Methamphetamine Addiction

      Rivaroxaban + ASA for Hip Fracture

      Antihypertensive Treatment for Postpartum Hypertension

      Penpulimab for Nasopharyngeal Cancer

      Radiofrequency Neurotomy Techniques for Neck Pain

      Robotic Surgery + HIPEC for Stomach Cancer

      TMS for Cervical Dystonia

      Intralesional Nivolumab for Precancerous Conditions

      Short-course Benznidazole for Chagas Disease

      Frequently Asked Questions

      How much do Adhd clinical trials in Pennsylvania pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Adhd clinical trials in Pennsylvania work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Adhd trials in Pennsylvania 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Pennsylvania for Adhd is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Pennsylvania several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Adhd medical study in Pennsylvania?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Adhd clinical trials in Pennsylvania?

      Most recently, we added MomMA Intervention for ADHD, CNS Stimulants for ADHD and Opioid Tapering for Opiate Dependence to the Power online platform.

      How to manage ADHD without Adderall?

      Think of ADHD care without Adderall as three pillars: 1) proven skills training such as cognitive-behavioral therapy or parent/teacher coaching, which meta-analyses show can meaningfully cut inattentive and impulsive symptoms; 2) daily habits that boost brain chemicals—consistent aerobic exercise, 7-9 hours of sleep, and a balanced, low-sugar diet—each backed by research to modestly improve focus; 3) targeted add-ons (omega-3 fish-oil supplements, mindfulness practice, or professionally guided neurofeedback) that have small but credible benefits for some people. Work with a clinician to combine, test, and adjust these pieces every few months so you know what is actually helping and can add non-stimulant medicines later if needed.

      Are we over diagnosing ADHD?

      Rates of ADHD diagnosis have climbed, and studies confirm that some children—especially the youngest in a class or from more advantaged families—get the label and medication they may not truly need. At the same time, girls, adults, and many minorities with real symptoms are often missed, so the issue is less “too much” diagnosis overall and more “diagnosis in the wrong people.” Asking for a full evaluation that checks symptoms in several settings and rules out sleep, mood, or learning problems is the best safeguard against both mistakes.

      What is the latest research on ADHD?

      Recent work is mapping ADHD on two fronts: cause and treatment. On the biology side, a 2023 genome-wide study involving >40 000 people pinpointed 30+ gene regions, MRI scans show disrupted communication between attention- and reward-circuits, and several studies find distinct gut-bacteria patterns in both kids and adults—together suggesting ADHD arises from a mix of genes, brain-network wiring and (still-early) gut influences. Translating this, clinicians now have newer options beyond classic stimulants—FDA-approved viloxazine XR, long-acting patches, the prescription video-game EndeavorRx, and small but promising trials of neurofeedback and cognitive training—so ask your doctor about standard medications plus these emerging tools that may soon allow more personalized care.

      Does Johnny Depp have ADHD?

      There is no credible public record—interview, court document, or medical statement—showing that Johnny Depp has been formally diagnosed with ADHD; the claim stems from unsourced online lists that repeat each other. Until Depp or a qualified clinician confirms otherwise, any statement that he “has ADHD” should be treated as unverified speculation; if you need information about ADHD, rely on a licensed health professional, not celebrity rumors.

      What is the 80 20 rule ADHD?

      For someone with ADHD, the 80/20 rule means spotting the 20 % of tasks or habits that create about 80 % of your desired results—then protecting time and attention to do those first, ideally when your medication or energy is at its peak. This cuts overwhelm because you give yourself permission to ignore low-impact busywork and instead break the high-impact tasks into small, doable steps (using timers, alerts, or an accountability partner). Think of it as a focusing lens, not a cure; pair it with your regular ADHD treatments and adjust the “vital 20 %” as your goals change.

      Is ADHD a disability?

      Yes—ADHD is treated as a disability when the symptoms are strong enough to “substantially limit” everyday activities like focusing, learning, or working, which is exactly how U.S. laws such as the ADA, Section 504, and Social Security define disability. A diagnosis alone isn’t enough; you need documentation that the condition is causing real-world problems, after which schools, employers, or benefit programs must consider reasonable supports (extra time, quiet workspace, flexible scheduling, etc.). If you think ADHD is holding you back, gather medical records and examples of how it affects your tasks and formally ask for accommodations or benefits under the relevant program.

      What makes ADHD people happy?

      Studies show that people with ADHD feel happiest when four things line up: (1) their core symptoms are tamed with medication and/or ADHD-specific therapy, (2) predictable routines, reminders, exercise, and good sleep cut daily chaos, (3) they spend real time in activities that match their high interests and creativity, and (4) they’re surrounded by family, friends, or support groups that understand ADHD rather than shame it. Put simply: treat the symptoms, externalize organization, lean into your passions, and stay connected to people who “get” you—those combined levers consistently raise quality-of-life scores for both kids and adults with ADHD.

      How much weight did you lose on ADHD medication?

      Weight loss on stimulant ADHD medicines is usually modest and highly individual—clinical trials show average drops of about 3–5 lb (1–2 kg) in the first month and roughly 6–10 lb (3–4 kg) over the first 3–6 months, with only one-third of people losing more than 5 % of their starting weight before the effect levels off. Weigh yourself (or your child) weekly; if you see more than a 10 % fall from baseline or a slowdown in growth, talk with the prescriber about dose timing, nutrition strategies, or switching to a non-stimulant option.

      What makes ADHD worse in adults?

      Anything that further strains the brain’s self-regulation system can flare adult ADHD: lack of sleep or exercise, chronic stress, unmanaged anxiety/depression, inconsistent medication or substance use, hormonal shifts, and chaotic, screen-heavy environments. Focus on the controllables—protect 7-9 h of sleep, move daily, eat regular balanced meals, keep spaces and schedules simple, treat co-existing mood issues, and take medication exactly as prescribed—then review persisting problems with your clinician.

      Is there still ADHD med shortage?

      Yes—into 2024 many pharmacies still report spot shortages of popular stimulant ADHD medicines, especially immediate-release Adderall, several methylphenidate/Concerta generics, and some Vyvanse doses, because factory slow-downs and federally capped production haven’t kept up with rising prescriptions. Availability varies week-to-week and by location, so call a few pharmacies early, ask if a different strength or brand is in stock, and have your prescriber ready to adjust the prescription or discuss a short-term non-stimulant alternative if needed.